CYCN vs. GRAY, OBSV, TRVN, VAXX, BNOX, CANF, EFTR, OGEN, VIRI, and HEPA
Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Graybug Vision (GRAY), ObsEva (OBSV), Trevena (TRVN), Vaxxinity (VAXX), Bionomics (BNOX), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Oragenics (OGEN), Virios Therapeutics (VIRI), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical preparations" industry.
Graybug Vision (NASDAQ:GRAY) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
In the previous week, Graybug Vision's average media sentiment score of 1.89 beat Cyclerion Therapeutics' score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.
Cyclerion Therapeutics received 18 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
Cyclerion Therapeutics' return on equity of -77.61% beat Graybug Vision's return on equity.
49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Comparatively, 13.1% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cyclerion Therapeutics has higher revenue and earnings than Graybug Vision.
Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.
Summary
Cyclerion Therapeutics beats Graybug Vision on 9 of the 10 factors compared between the two stocks.
Get Cyclerion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclerion Therapeutics Competitors List
Related Companies and Tools
